Tavaborole is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophyte. It is available as topical solution. MedsAcross supplies Tavaborole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophyte. Tavaborole topical solution is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Source: US FDA prescribing information
Tavaborole topical solution is an oxaborole antifungal.
Source: US FDA prescribing information
Apply tavaborole topical solution to affected toenails once daily for 48 weeks. Tavaborole topical solution should be applied to the entire toenail surface and under the tip of each toenail being treated. Tavaborole topical solution is for topical use only and not for oral, ophthalmic, or intravaginal use. • Apply tavaborole topical solution to affected toenails once daily for 48 weeks. • Tavaborole topical solution should be applied to the entire toenail surface and under the tip of each toenail being treated. • For topical use only. • Not for oral, ophthalmic, or intravaginal use.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Common adverse reactions occurring in ≥1% in subjects treated with tavaborole topical solution included application site exfoliation, ingrown toenail, application site erythema, and application site dermatitis.
Source: US FDA prescribing information
Store at 20–25°C (68–77°F), excursions permitted to 15–30°C (59–86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Tavaborole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tavaborole 43.5 mg/mL topical solutionTopicalGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 7 July 2014 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Tavaborole and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Tavaborole on 7 July 2014, according to Drugs@FDA.
No listed presentation of Tavaborole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tavaborole is classified under ATC code D01AE24 (Tavaborole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.